All Type of News
Reason why melanoma therapy Zelboraf failed to be registered for insurance benefit
A Roche Korea’s metastatic melanoma treatment ‘Zelboraf(vemurafenib)’ is a drug which still has not been registered in the drug insurance benefit list for more than 4 years after acquiring commercialization approval i...
Public hearing to legislate ‘Public Pharma Establishment Law’
Assemblyperson Mi-Hyuk Kwon(proportional representative) from The Minjoo Party is planning to hold a public hearing to legislate the ‘Public Pharmaceutical Company Establishment and Management Act’ in response to publ...
Will Avastin be administered in ophthalmology field having no approval?
The government is working on legislating an act to allow hospitals and clinics having no IRB(Institutional Review Board) to widely use pharmaceutical products officially notified by President of the Health Insurance R...
Samsung Bioepis begins to nullify Herceptin’s patent
Samsung Bioepis has started to prepare for a launch of Herceptin(generic name: trastuzumab) biosimilar, a breast cancer treatment, in Korea.
According to the Intellectual Property Tribunal, Samsung Bioepis filed a (...
Amgen overcomes insurance benefit for Blincyto
It is expected Amgen will begin to aggressively target the domestic antibody market.
In the ‘Amendment to the Public Announcement about Drugs Prescribed and Administered on Cancer Patients’ notified by the Health Ins...
Countdown for AIDS treatment overcoming ‘Stribild’ to launch in Korea
A Gilead Sciences’ new 4-substance complex drug ‘Genvoya’ acquired approval to commercialize in Korea. Thus, Gilead is expected to consolidate its position in the HIV treatment market.
According to the industry conc...
Multinational companies’ supply of products with less than 6-month expiration date
Multinational pharmaceutical companies have caused issues as constantly providing products with less than 6-month expiration periods to pharmaceutical distribution companies as an excuse of the out-of-stock crisis on ...
CorePharm succeeds in avoiding Astellas’ patent by salt modification
While a series of domestic companies’ challenges to substance patents all went in vein after implementation of the Patent Linkage System on March 2015, a ruling was made in favor of a Korean challenger at the defensiv...
“Topic is illegality,” multinational pharmas to stand as witness at National Inspection
Two multinational pharmaceutical companies will be summoned for this year’s national inspection. They are Novartis Korea and Janssen Korea; its topic is ‘illegality.’
The Ruling-Opposition Parties’ Room for National ...
“Pharma industry must be cautious on custom to provide KRW 400k accommodation per day”
The ‘Anti-Corruption and Bribery Prohibition Law,’ also known as the ‘Kim Young-Ran Law,’ is about to be enforced in less than 10 days.
While guidelines for governmental departments and the press have been released, ...
Which are outstanding tetravalent vaccines even for the young?
Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer
Who will be the next Pharmaceutical Safety Bureau Director?
Celltrion completes clinical trials for Remsima SC for European approval
Sales listed pharmas made in the first half of the year
April
January
February
March
April
May
June
July
August
September
October
November
December
2025
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
30 | 31 | 1 | 2 | 3 | 4 | 5 |
6 | 7 | 8 | 9 | 10 | 11 | 12 |
13 | 14 | 15 | 16 | 17 | 18 | 19 |
20 | 21 | 22 | 23 | 24 | 25 | 26 |
27 | 28 | 29 | 30 | 1 | 2 | 3 |
00:00
01:00
02:00
03:00
04:00
05:00
06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00
22:00
23:00
